Statement of Principles concerning malignant neoplasm of the colon and rectum (Balance of Probabilities) (No. 20 of 2022)

This Statement rests on a small set of core concepts that determine how it will be applied in adjudication. They are: the statutory condition definition, the “balance of probabilities” standard and the factor test, the temporal linking requirements to service, and specific measurement definitions. Each is deployed in the text with prescriptive detail.

1. Statutory condition definition. The instrument defines “malignant neoplasm of the colon and rectum” as a primary epithelial cancer of the colon or rectum and expressly excludes several other tumours and lymphomas (s7(2)(a)‑(b)). It clarifies anatomical scope by notes on the extent of colon and rectum (s7 notes). Although ICD‑10‑AM codes C18‑C20 are referenced, the statutory meaning derives from the textual definition (s7(3)‑(4)).

2. Balance of probabilities and factor test. The Statement confirms the Repatriation Medical Authority’s conclusion that, on sound medical‑scientific evidence, it is more probable than not that the condition can be related to relevant service (s8). It converts that conclusion into an adjudicative test: at least one of the enumerated factors in s9 must exist, and that factor must be related to the person’s relevant service (s9, s10(1)). Thus the instrument operates as a two‑part gate: an approved medical/epidemiological link, then factual establishment of a listed factor tied to service.

3. Temporal thresholds and “clinical onset”. Most factors include specific duration and timing requirements relative to “clinical onset of malignant neoplasm of the colon or rectum” (for example s9(3)‑(4), (5), (7), (10)‑(16)). The instrument uses the notion of clinical onset repeatedly but does not define “clinical onset” within the text or Schedule. The absence of an express definition should be noted as it affects proof and timing analyses.

4. Quantitative exposure metrics and methodological anchors. Several factors require quantitative proof. Examples are cumulative equivalent dose of ionising radiation with a threshold 0.5 sievert and a specified dose reconstruction methodology referenced to an ARPANSA guide in force on 2 August 2017 (s9(7); Schedule cumulative equivalent dose). Smoking is measured in pack‑years with a defined equivalence to grams of smoking tobacco (s9(10); Schedule one pack‑year). Alcohol use is measured in total kilograms consumed with calculation by Australian standard of 10 grams per standard drink (s9(11) note). Dietary factors use grams per day of red meat or processed meat and minimum durations (s9(16)(c)‑(d); Schedule definitions of red meat and processed meat product). Obesity is defined by BMI thresholds or waist circumference with numeric cutoffs (Schedule being obese, BMI). Physical activity is measured by METs with 1 MET defined in the Schedule (s9(16)(a); Schedule MET).

5. Interaction with other Statements of Principles. Where a factor in s9 refers to an injury or disease that is subject to another Statement, the terms of that other Statement apply as in force (s11). That creates a rule of precedence and cross‑reference rather than duplication.

6. Scope of relevant service. The instrument applies to claims to which s120B of the VEA or s339 of the MRCA apply (s5). “Relevant service” is defined in Schedule 1 and includes eligible war service, defence service and peacetime service under the MRCA, with exclusions stated for certain service categories (Schedule relevant service).

7. Death and terminal event linkage. The instrument includes deaths from the malignant neoplasm where the cancer contributed to a terminal event such as pneumonia or cardiac arrest, with a terminal event defined in Schedule 1 (s7(5); Schedule terminal event).

These concepts determine evidentiary priorities. Decision makers will need to establish not just that a factor is present, but that it met the stated magnitude and timing thresholds and that the factor is related to the person’s relevant service. The instrument ties many of the technical thresholds to external measurement standards and guides, for example the ARPANSA cumulative dose guide and the ICD‑10‑AM codes, thereby anchoring determinations to recognisable scientific tools.

The instrument is directed at persons making claims under specific veterans’ compensation and rehabilitation regimes and at the authorities who adjudicate those claims. It affects:

• Claimants who have, or have died from, malignant neoplasm of the colon or rectum and who seek a finding that their condition is connected with relevant service for the purposes of the VEA or MRCA. The instrument expressly applies to claims to which s120B of the VEA or s339 of the MRCA applies (s5). It also refers to “veterans or members of the Forces” in s8, consistent with the institutional role of the Repatriation Medical Authority.
• Decision makers and medical assessors who must apply the Statement in processing those claims. The Repatriation Medical Authority sets the Statement under s196B(3) VEA (s3); adjudicators will use the Statement as the medical‑science standard when determining whether a condition is connected with service.
• Medical practitioners and expert witnesses preparing medical reports for claims. The Statement lays down the factors and the measurement rules (Schedule 1), including thresholds for exposures and durations that clinicians must address.
• Administrators responsible for evidence gathering and dose reconstruction. For example, when ionising radiation is asserted, dose calculations are to be done in accordance with the ARPANSA guide referenced in the Schedule (cumulative equivalent dose), and asbestos exposure is measured by cumulative hours with different thresholds for enclosed spaces and open environments (s9(8)‑(9)). That places practical work on record retrieval and exposure assessment on those preparing claims and on agencies undertaking investigations.

The instrument also indirectly affects service record custodians, occupational health providers and treating clinicians because the instrument’s thresholds create demand for documentary evidence: smoking history quantified in pack‑years with cessation timing, records of colorectal screening and of any prevented access or declined opportunities, documentation of obesity metrics over time (BMI, waist circumference), dietary histories quantified to grams per day over specified windows, records of therapeutic radiation including field and dose, and histories of asbestos disturbance work with cumulative hours. The Schedule supplies the exact measurement units and equivalences for many of these items and thus prescribes what evidence will be probative.

Finally, s11 creates an incidence where other Statements of Principles interact. If a factor in s9 refers to an injury or disease already covered by another Statement, then the claimant and decision maker must consult that other instrument and apply its terms. This affects cross‑claim situations where, for example, a factor references a disease with its own Statement. The instrument therefore affects the workflow of claims that involve multivariate medical histories or multiple applicable Statements.

Note that the instrument does not itself create entitlements or payments, and it does not specify administrative processes. It is a medical science instrument intended to be used in claims under the VEA and MRCA as indicated in s5.

This Statement imposes no direct duties in the sense of operational obligations or sanctions, but it establishes determinative rules that create duties and rights within the claims process when used by decision makers.

Rights arising from the instrument

• The right to have a claim assessed against the standards set by the Statement. Because the instrument is a Statement of Principles under subsection 196B(3) of the VEA, its content is the medical‑scientific yardstick for assessing whether malignant neoplasm of the colon and rectum is related to relevant service (s3, s8). Claimants thus have the right to expect adjudicators will apply the factors and definitions in s9 and Schedule 1 in establishing causation on the balance of probabilities.
• The right to rely on any one factor listed in s9, provided that the factor is established and is related to the person’s relevant service (s9, s10(1)). The test is conjunctive only insofar as at least one factor must exist and be related to service; it is not necessary to show multiple factors.

Duties arising from the instrument

• Decision makers and assessors have the duty to apply the Statement’s factors and definitions to claims. They must determine whether at least one of the s9 factors is present and whether that factor is related to relevant service (s9, s10). Where a factor refers to an injury or disease covered by another Statement, decision makers must apply that other Statement’s terms (s11).
• The duty to follow specified measurement methodologies. For example, where ionising radiation doses are asserted, the Schedule specifies that cumulative equivalent dose is to be calculated in accordance with the ARPANSA guide in force on 2 August 2017 (Schedule cumulative equivalent dose). Medical assessors and those reconstructing doses are required to adopt that methodology when applying this Statement.
• The duty to respect temporal and magnitude thresholds in s9. Many factors include specific duration requirements and timing relative to the clinical onset. Assessors must check whether the factual record satisfies those minima, such as smoking thresholds of at least 30 pack‑years and commencement at least five years before clinical onset, with cessation timing limits (s9(10) and Schedule).

Limits on duties and rights

• The Statement does not itself adjudicate claims or award benefits. It is an authoritative medical standard that must be applied under the relevant entitlement provisions of the VEA and MRCA. The instrument therefore guides duties of decision makers who act under those Acts, rather than creating administrative procedures or payment rules itself (s5).
• s10(2) places a constraint on s9(17). The factor about inability to obtain appropriate clinical management for malignant neoplasm applies only to material contribution or aggravation where the cancer was suffered or contracted before or during (but did not arise out of) relevant service. That modulates the right to rely on s9(17) and the duty of decision makers to apply it only in prescribed circumstances.

Evidential consequences

• The Statement fixes what must be proved to discharge the connection element of a claim. The duty of claimants is therefore to produce evidence that matches the measurement constructs in the Schedule, for example records necessary to calculate pack‑years, BMI, waist circumference or dietary histories, or service postings and duties relevant to asbestos exposure. Decision makers have the reciprocal duty to evaluate that evidence against the thresholds in the instrument.

In sum, the Statement generates rights to have claims tested by its specified medical criteria and duties on assessors to apply its factors, definitions and external methodological anchors in making causal determinations under the VEA and MRCA frameworks.

The instrument is a Statement of Principles and does not itself create criminal offences, civil penalties or an explicit enforcement regime within its text. Its primary effect is evidentiary and determinative within the statutory claims processes governed by the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004.

Practical enforcement and sanctioning consequences arise indirectly through administrative decision making:

• The Statement provides the medical‑scientific basis by which decision makers determine whether malignant neoplasm of the colon and rectum is connected with relevant service on the balance of probabilities (s8, s9, s10). A finding for a claimant based on this Statement can lead to entitlements under the VEA or MRCA when those Acts provide for liability or benefits; conversely, failure to establish a listed factor related to service will normally result in a negative entitlement decision. The instrument therefore affects the outcome of administrative enforcement of benefit schemes even though it contains no penal clauses.
• There is no penalty provision in the text for false statements, fraud, or non‑compliance with record requests. Any penalty mechanisms or sanctions for dishonest claims or failure to provide information would be located in the underlying entitlement Acts and associated regulations, not in this Statement. The instrument does not purport to alter or prescribe those enforcement mechanisms.
• The Schedule requires use of particular methodologies for certain technical matters, for example cumulative equivalent dose calculations as per an ARPANSA guide in force on 2 August 2017 (Schedule cumulative equivalent dose). Non‑adherence to those prescribed methodologies by dose reconstruction authorities or expert witnesses may undermine the probative weight of evidence, and could be contested in administrative review or judicial processes, but the Statement itself does not specify corrective sanctions.

Administrative appeal and review implications

• Because the Statement operates within the VEA and MRCA claims systems, adverse decisions that apply the Statement can be subject to internal review, statutory review pathways and judicial review in accordance with those Acts and general administrative law. The Statement is authoritative for medical causation, and courts and tribunals will expect decision makers to explain how they applied the Statement when rejecting or accepting a claim. The Statement itself does not set review procedures, timelines or remedies.

Enforcement risk for agencies and experts

• Entities responsible for dose reconstruction, clinical assessments and service records disclosure will be expected to use the measurement methods and definitions the Statement prescribes. Failure to apply the stated methodologies, such as the ARPANSA guide for cumulative dose or the pack‑year equivalence for tobacco, may result in evidentiary weaknesses and administrative challenge. The Statement thus imposes a de facto compliance obligation on professionals whose work supports claim decisions, but again it imposes no separate statutory penalties in the instrument.

In short, the instrument imposes no standalone penalties. Its enforcement effect is channelled through the statutory claims machinery by determining the medical criteria decision makers must apply. Any sanctioning or appeal consequences flow from the underlying Acts and from administrative and judicial scrutiny of how the Statement was applied.

The Statement is created under the Veterans' Entitlements Act 1986, and it operates within the legal architecture of that Act and the Military Rehabilitation and Compensation Act 2004. The instrument itself specifies the interaction points and cross‑references that decision makers must respect.

Primary statutory anchoring

• The instrument is made under subsection 196B(3) of the VEA (s3). It applies to claims to which s120B of the VEA or s339 of the MRCA applies (s5). The Statement therefore functions as a medical‑science standard to be applied when decision makers exercise powers under those provisions. The instrument does not displace or modify the substantive entitlement provisions in the VEA or MRCA; rather it supplies the medical causation criteria decision makers must use.

Cross‑instrument interaction

• s11 provides a direct rule for interaction with other Statements of Principles. If a factor in s9 refers to an injury or disease for which a separate Statement has been determined under subsection 196B(3) of the VEA, then the factors in that other Statement apply in accordance with its terms as in force. This creates a legal hierarchy in which discrete Statements address their specific medical matters and must be consulted when factors overlap across instruments. The practical effect is that adjudicators must navigate multiple Statements where a particular exposure or disease has its own instrument.

Methodological dependencies on external guides and classifications

• The instrument references the ICD‑10‑AM codes C18, C19 and C20 and specifies the edition and effective date (Tenth Edition, effective 1 July 2017) and the copyright holder (Independent Hospital Pricing Authority) (s7(3)‑(4)). Decision makers using ICD coding must therefore be aware of the edition specified in the Statement when mapping diagnoses.
• For ionising radiation, the Schedule mandates dose calculation methodology as set out in the ARPANSA guide titled Guide to calculation of "cumulative equivalent dose" for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986, as in force on 2 August 2017 (Schedule cumulative equivalent dose). This imposes a technical dependency on ARPANSA guidance and on whatever legal or evidentiary rules govern its use in the claims process.

Relationship to underlying entitlement law and adjudication

• The Statement determines medical causation for administrative purposes but its legal effect depends on the provisions of the VEA and MRCA under which entitlements are claimed. For example, s5 confirms this Statement applies to claims falling within particular sections of those Acts. Outcomes under the Statement will therefore interact with those Acts’ procedural rules, limitation periods, review rights and payment provisions. The Statement does not specify those procedural rules.

Relevance to other statutory regimes

• The Statement does not purport to alter or engage other statutory regimes such as workers’ compensation or public health laws. However, factual findings made against the Statement can have evidentiary or persuasive value in other contexts, because it codifies a view about medical causation. The instrument itself does not specify collateral effect in other statutory forums; any such effect would be a matter for those fora to consider.

Temporal interaction and repeal

• The instrument repeals the prior Statement No. 38 of 2013 (s4). Decision makers must therefore apply the 2022 Statement from its commencement date (s2) for claims it covers. Where previous Statements were applied to earlier claims, their terms remain relevant for those matters to the extent of that temporal application.

In summary, the Statement operates as an authoritative medical standard within the VEA and MRCA claims framework, cross‑refers to external medical classification and technical guidance, and requires decision makers to consult other Statements where factors overlap. It interacts with those other laws and instruments by directing the medical assessment component of entitlement determinations, while procedural and remedial consequences remain governed by the underlying legislation.

The instrument contains a limited and explicit amendment history in its own text. The key items are the repeal of an earlier Statement and the dates of enactment and commencement.

• Repeal of previous Statement. Section 4 explicitly repeals the Statement of Principles concerning malignant neoplasm of the colorectum No. 38 of 2013 (Federal Register of Legislation No. F2013L01130), which had been made under subsections 196B(3) and (8) of the VEA. The text does not include the 2013 instrument’s contents, but the repeal is absolute for the subject matter covered by the 2022 Statement (s4).

• Commencement date. Section 2 states this instrument commences on 31 January 2022. That makes clear the operational start date for application to claims governed by the VEA and MRCA provisions specified in s5.

• Date of determination. The instrument is dated 24 December 2021, and the formal seal and Chairperson identification appear in the instrument (front matter). The effective commencement follows the determination date by a defined interval, with the commencement clause giving the operative start.

• No other amendments recorded. The instrument does not record any prior amendments to itself, nor does it amend other primary legislation. The Schedule contains definitions current as at the instrument but does not indicate subsequent modification. Any later amendments to this Statement would be contained in later instruments; none are recorded within the text provided.

• External guidance referenced as fixed to a date. The Schedule references the ARPANSA guide "as in force on 2 August 2017" for cumulative equivalent dose calculations. That is an example of the instrument fixing an external technical methodology to a particular version or date rather than leaving it open‑ended. Any change in that external guide after 2 August 2017 would not alter the Statement unless the Statement itself were amended.

• Interaction with other Statements as updated. Section 11 requires that where a factor in s9 refers to an injury or disease covered by another Statement, then “the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.” This language creates a dynamic element: other Statements may be updated, and those updated terms will apply when s9 refers to matters covered by them. By contrast, the radiation methodology is fixed to a specific guide date.

For practitioners, these elements mean: the 2022 Statement replaced the 2013 Statement as of 31 January 2022; external technical references may be fixed to particular versions; and cross‑references to other Statements carry forward any subsequent updates to those other instruments. The instrument itself provides no further amendment history or transitional provisions beyond the repeal and commencement clauses.

The instrument does not contain any litigation history. It is a Statement of Principles instrument made by the Repatriation Medical Authority and the text supplied contains no references to judicial or tribunal decisions, settled litigation, or legal challenges arising from the instrument itself.

Practical observations about litigation risk and use in dispute resolution

• The Statement is a statutory medical standard used within VEA and MRCA claims processes. While the instrument contains no litigation history, findings that rely on this Statement will be susceptible to administrative review and judicial review within the frameworks set by the VEA, the MRCA and administrative law. Judicial or tribunal scrutiny will focus on whether decision makers properly applied the Statement’s factors and definitions when reaching causation findings.

• Potential areas for dispute, given the instrument’s content, include: interpretation of “clinical onset” where the text does not define the term; application of duration and timing thresholds for factors such as asbestos exposure hours, radiation dose latency, smoking pack‑years and the timing of cessation; the method and adequacy of dose reconstruction under the ARPANSA guide; and whether a particular exposure or condition is “related to” the person’s relevant service in the sense required by s10(1). Because the instrument sets quantitative thresholds, disputes may centre on the quality and sufficiency of evidence to meet those thresholds.

• Cross‑instrument disputes may arise under s11 where an element of s9 refers to another Statement of Principles. Parties may contest which Statement applies, or whether decision makers used the correct, current version of an overlapping Statement. The text anticipates such cross‑references by instructing that the other Statement’s terms apply “as in force from time to time” (s11), which could itself be a subject of litigation if there is ambiguity about which version applied.

• While no cases are named in the instrument, claimants and decision makers should expect that contested cases going to tribunal or court will engage the specific measurements and external guides the Statement embeds, for example the pack‑year equivalence rules in the Schedule or the ARPANSA dose reconstruction methodology. Expert evidence will likely be necessary to establish or rebut compliance with the Statement’s thresholds.

Because the instrument is silent on prior litigation, practitioners should search administrative and tribunal records, and case law databases, for decisions that apply the 2022 Statement or the replaced 2013 Statement in order to understand how courts and tribunals have treated similar issues. The instrument itself does not report any such decisions.

The instrument contains several technical, evidential and interpretive traps that can affect both claimants and decision makers. These are practical “gotchas” grounded in specific wording, definitions, and procedural interactions in the Statement and Schedule.

1. The meaning and absence of a definition for “clinical onset”. Many factors are timed relative to “clinical onset of malignant neoplasm of the colon or rectum” (for example s9(3)‑(4), (5), (7), (10), (12), (15)‑(16)). The instrument uses that term repeatedly but does not define it in the Schedule. Practitioners must therefore anticipate disputes about when clinical onset occurred, and prepare medical evidence that locates onset clearly. The lack of a textual definition invites reliance on clinical records and expert interpretation.

2. Strict quantitative thresholds. The Statement requires specific magnitudes and durations. Examples include:

• Tobacco smoking: at least 30 pack‑years and commenced at least 5 years before clinical onset, with cessation limits if smoking stopped (s9(10); Schedule one pack‑year). The Schedule equates one pack‑year with 7,300 grams of smoking tobacco, creating an unusual conversion to weight that must be handled carefully in evidence.
• Alcohol: cumulative consumption of at least 500 kilograms before clinical onset, with alcohol consumption calculated by Australian standard of 10 grams per standard drink (s9(11) note). Claimants must translate typical drinking histories into total kilograms of alcohol, which can be complex and imprecise.
• Obesity: being obese for at least 10 years within the 30 years before clinical onset, with obesity defined by BMI ≥ 30 or waist circumference thresholds (Schedule being obese, BMI). Longitudinal anthropometric data will often be scarce.
• Radiation: a cumulative equivalent dose of at least 0.5 sievert received at least 10 years before clinical onset, with dose reconstruction to be calculated in accordance with an ARPANSA guide dated 2 August 2017 (s9(7); Schedule). Quality dose reconstruction requires technical expertise and reliable exposure data.
• Asbestos: differing cumulative hour thresholds for enclosed spaces (2,000 hours) versus open environments (6,000 hours) and a 10‑year latency requirement, with the first inhalation required to commence at least 10 years before clinical onset (s9(8)‑(9)). Differentiating enclosed from open exposure and proving cumulative hours can be difficult.
• Diet and activity: specific gram per day thresholds for red meat and processed meat products and MET thresholds for physical activity for colon cancer only (s9(16)). Dietary recall over decades is inherently imprecise.

3. Prevention of screening or treatment factors require state of access and subsequent actions. s9(3) addresses being prevented from accessing clinical screening within the 5 years before clinical onset and contains two subrequirements if screening later resumed: (a) there has been no normal test result, and (b) opportunity for subsequent clinical screening has not been declined. This combination requires not just proof of a period without screening but also proof of follow‑up behaviour and test results. Similarly, s9(4) requires being prevented from accessing appropriate treatment for precancerous lesions within 5 years before clinical onset. Documentary proof of opportunity, invitations, or administrative denial will be necessary.

4. s9(17) limited scope via s10(2). The factor in s9(17) about inability to obtain appropriate clinical management for malignant neoplasm applies only, per s10(2), to material contribution or aggravation where the cancer was suffered or contracted before or during (but did not arise out of) relevant service. This is a narrow window and could preclude reliance on s9(17) where cancer arose out of service or where onset occurred after service.

5. Cross‑reference to other Statements. s11 requires that factors referring to injuries or diseases covered by another Statement be dealt with under the terms of that other Statement “as in force from time to time”. Practitioners must identify and apply the current versions of relevant Statements, which can create complexity where multiple Statements and versions may be relevant.

6. Dependence on external technical documents and fixed dates. The Schedule binds dose reconstruction to a specific ARPANSA guide “as in force on 2 August 2017”. That fixes methodology to a snapshot in time and can create issues where subsequent scientific practice has evolved. Similarly, the ICD‑10‑AM edition is specified. Users must ensure they are using the version the Statement prescribes.

7. Exact anatomical limits. The instrument’s notes define the extent of the colon and rectum with exclusions such as the rectosigmoid junction not being part of the colon in the Statement’s note, which can be material when a tumour’s anatomical site is borderline (s7 notes).

8. Measurement equivalences that are non‑intuitive. The pack‑year equivalence in grams of tobacco, the calculation of alcohol in kilograms, and the dietary gram thresholds require conversions that are not routine for many clinicians and necessitate careful calculation and documentation.

9. No penalties or procedural detail in the instrument. The Statement does not supply evidence rules, procedural timelines or appeal pathways. Those are located in the underlying VEA and MRCA, so practitioners must coordinate the medical evidence required here with the procedural rules elsewhere.

Overall, the instrument’s technical specificity is its strength and its risk. It can make causation determinations more objective, but it shifts the burden onto claimants to assemble precise, often longitudinal, quantitative evidence and onto decision makers and experts to apply specified methodologies and to resolve definitional ambiguities such as “clinical onset”.

Compliance, in the sense relevant to this Statement, is about preparing and presenting evidence that satisfies the Statement’s factors and measurement rules so that a decision maker can find a connection to relevant service on the balance of probabilities. The following practical steps are grounded in the instrument’s text and Schedule definitions.

1. Identify the operative provisions and scope. Confirm the claim falls within the categories in s5, that is, it is a claim to which s120B VEA or s339 MRCA applies. Confirm the diagnosis fits the instrument’s definition of malignant neoplasm of the colon and rectum (s7(2)‑(4)), including that the tumour is not an excluded histology such as carcinoid or lymphoma.

2. Determine which s9 factor(s) are relevant for the individual. Review the 17 factors in s9 in detail. Select the most readily provable factor that matches the claimant’s history, for example pre‑existing familial adenomatous polyposis (s9(1)), a documented colorectal adenoma in the affected site (s9(2)), documented therapeutic radiation encompassing the affected region (s9(6)), cumulative radiation dose above 0.5 sievert (s9(7)), or the asbestos exposure hour thresholds in s9(8)‑(9). For death claims, gather records that link the malignant neoplasm to a terminal event listed in Schedule 1 (s7(5) and Schedule terminal event).

3. Assemble documentary and clinical evidence aligned to the Statement’s measurements.

• Smoking history. Calculate pack‑years as per the Schedule’s rules. Document the daily cigarette-equivalent consumption and duration, and establish commencement and cessation dates relative to clinical onset. Use the Schedule’s equivalence (one pack‑year equals 20 cigarettes per day for a year, or 7,300 grams of tobacco) when converting non‑cigarette tobacco use.
• Alcohol history. Translate drinking history into total kilograms of alcohol utilising the Australian standard of 10 grams of alcohol per standard drink. Provide contemporaneous records where possible, such as medical notes, hospital records, or occupational health records.
• Obesity and anthropometrics. Provide BMI calculations over time using BMI = W/H2 with documented weights and heights. Where BMI is not available historically, obtain any clinical records with waist circumference measurements to apply the Schedule’s waist cutoffs for males and females.
• Diet and physical activity. For red and processed meat thresholds and fibre intake, prepare diet histories that quantify grams per day over the specified periods. For physical activity, quantify exercise in METs and document periods of inactivity meeting the stated thresholds (s9(16)(a); Schedule MET).
• Radiation exposure. Compile all therapeutic and occupational radiation records, and engage duty experts to perform dose reconstruction in accordance with the ARPANSA guide specified in the Schedule. Ensure that latency requirements are met, such as dose being received at least 10 years before clinical onset (s9(7)).
• Asbestos exposure. Document work tasks, locations, durations and whether environments were enclosed or open. Calculate cumulative hours and confirm the first exposure commenced at least 10 years before clinical onset (s9(8)‑(9)). Where debris or legacy contamination is involved, note the Schedule’s observation that disturbance of dust may produce exposure.
• Screening and treatment prevention. For s9(3) and s9(4), gather health service records, correspondence about screening invitations, cancellation records, military evacuation or deployment records that support inability to access screening or treatment within the 5‑year window before clinical onset. If screening later resumed, provide all subsequent test results and demonstrate whether normal test results occurred and whether screening opportunities were declined.
• Pre‑existing diseases. For inflammatory bowel disease, diabetes mellitus, schistosomiasis and acromegaly, provide diagnostic records and show durations that meet the minima set out in s9 (for example inflammatory bowel disease for at least 3 years before clinical onset, s9(5)).

4. Address the “relation to relevant service” requirement. s10(1) requires the factor to be related to the relevant service rendered by the person. Assemble service records, posting histories, duty statements and contemporaneous medical records that link exposures or prevented access to service periods defined as “relevant service” in the Schedule (eligible war service, defence service, peacetime service under MRCA). If relying on s9(17), ensure the additional constraint in s10(2) is met.

5. Use the correct external versions. For ICD code references, use the Tenth Edition ICD‑10‑AM effective 1 July 2017 as cited (s7(4)). For radiation dose reconstructions, use the ARPANSA guide “as in force on 2 August 2017” per the Schedule. Where s11 refers to other Statements, identify and use the current versions of those Statements “as in force from time to time.”

6. Provide expert affidavit or report evidence for technical issues. For dose reconstruction, asbestos exposure quantification, diet and long latency exposures, engage appropriately qualified experts who can link the factual record to the Statement’s thresholds, and who will apply the methodologies the Statement prescribes.

7. Anticipate gaps in longitudinal data. The Statement’s thresholds often require longitudinal evidence. Where direct contemporaneous data are absent, build a coherent evidentiary chain using service records, secondary medical records, occupational logs, witness statements and expert opinion. Be explicit about any assumptions used in calculations and the basis for those assumptions.

8. Be prepared to address “clinical onset” timing. Because clinical onset is not defined in the Statement, present medical evidence identifying the earliest objective clinical manifestation consistent with the treating clinicians’ notes, imaging and pathology that can be used to locate onset for timing requirements.

9. Prepare for cross‑Statement issues. Where a factor points to another Statement of Principles, identify that other instrument and ensure evidence complies with it, because s11 requires application of that Statement’s terms.

10. Document attempts to obtain care. For factors predicated on lack of access to screening or treatment, document steps taken to obtain care, reasons access was denied or constrained, and any institutional or geographic obstacles. If screening subsequently resumed, ensure test results and the claimant’s response to offered screening are clearly recorded.

By following these steps and adhering to the measurement rules and temporal thresholds in s9 and Schedule 1, claimants and advisers will align evidence to the precise criteria the Repatriation Medical Authority has prescribed for malignant neoplasm of the colon and rectum. The Statement’s specificity demands careful quantitative translation of histories and robust expert input for technical claims such as radiation dose and asbestos hour calculations.